Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 12/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | PKLR | P30613 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.35 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 3/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18513605 | 0.94 | PKM (0.38) | PKMCA9PKLRNPC1MAPK13 | |
| SCHEMBL16320837 | 0.82 | AHR (0.43) | MAOB | |
| SCHEMBL18513800 | 0.81 | — | — | |
| SCHEMBL30320598 | 0.81 | PKM (0.40) | PKMCA9NPC1MAPK13MAPK12 | |
| SCHEMBL21382268 | 0.81 | PKM (0.40) | PKMCA9NPC1MAPK13MAPK12 | |
| SCHEMBL15463659 | 0.75 | CYP11B1 (0.37) | CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL19278654 | 0.75 | CA9 (0.52) | PKMCA9PKLRNPC1MAPK13 | |
| SCHEMBL17042127 | 0.74 | CA9 (0.50) | CA9NPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL422134 | 0.74 | PDE3B (0.44) | PKMCA9NPC1MAPK13MAPK12 | |
| SCHEMBL12533550 | 0.74 | P2RX7 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200299262-A1 | ARYL-SUBSTITUTED DIHYDROQUINOLINONES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | EPIGENETIX, INC. | 2020-09-24 | — | — | US | disclosed |
| US-20200299262-A1 | ARYL-SUBSTITUTED DIHYDROQUINOLINONES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | EPIGENETIX, INC. | 2020-09-24 | — | — | US | disclosed |
| EP-3334717-B1 | ARYL-SUBSTITUTED DIHYDROQUINOLINONES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | NEOMED INST (CA) | 2020-07-01 | — | — | EP | disclosed |
| EP-3334717-B1 | ARYL-SUBSTITUTED DIHYDROQUINOLINONES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | NEOMED INST (CA) | 2020-07-01 | — | — | EP | disclosed |
| WO-2017024408-A1 | ARYL-SUBSTITUTED DIHYDROQUINOLINONES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | NEOMED INSTITUTE (CA) | 2017-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299262-A1 | ARYL-SUBSTITUTED DIHYDROQUINOLINONES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | BRPF3, BRD4, BRDT | PKM 2752/4885CA9 4195/4885PKLR 3072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.